Powered by

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

Aug 06, 2019 - Thomson Reuters ONE

Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines

LONDON and WASHINGTON, Aug. 06, 2019 (GLOBE NEWSWIRE) -- GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently ava...